Mario Balsa· @MarioBalsaMD · X·· 1 天前评分45
正文 · 原文
From the podium to your screen!! Before the applause is even over!
@OncoAlert #Podium2Screen brings @stolaney1’s #ESMO26 evERA biomarker data straight to the feed: giredestrant + everolimus maintained benefit across ctDNA burden, ESR1 variants and poor-prognosis subgroups.
At ESMO, the data move fast. OncoAlert moves faster 😏
@_SEOM @myESMO
115 浏览 · 4 赞 · 1 转发 · 0 回复
🎬 New OncoAlert #Podium2Screen 🎬 from #ESMO26 Our #BreastCancer faculty member @stolaney1 🇺🇸(@DanaFarber) walks us through her #ESMO26 presentation: biomarker analyses from evERA @elmayermd, @stolaney1, @GregoryAVidal, @jhaveri_komal, @breastoncdoc, @DrWGradishar, @NaokiNiikura, @FavretMD, @DraAlfie, @hoperugo 🔹 Giredestrant + everolimus kept its PFS benefit regardless of ctDNA fraction 🔹 Benefit held across ESR1 variants, including Y537 (HR 0.35) 🔹 Benefit also held in poor-prognosis subgroups (TP53, GATA3, RB1) Pinging OncoAlert Breast Cancer Faculty @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc @Lucarecco @Dr_Oncologista @guiandri76在 X 查看被引用的帖子
来源：Mario Balsa · x.com